Excellent Early Experience Reported With Edwards SAPIEN 3 Transcatheter Valve by St. Paul's Doctor John Webb
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that the first data on its most advanced commercially available transcatheter aortic heart valve, the Edwards SAPIEN 3 valve, were presented in a late-breaking clinical trial session at EuroPCR 2014 by John Webb, M.D., director of interventional cardiology and cardiac catheterization laboratories at St. Paul's Hospital, Vancouver, and professor of cardiology at the University of British Columbia.
The presentation concluded that outcomes at 30 days were excellent. Transfemoral SAPIEN 3 implantation was associated with a very low mortality of 2.1 percent, a stroke rate of 1.0 percent, and very few access-site complications. In addition, 96.6 percent of patients had ≤ mild paravalvular leak. There was no severe paravalvular leak.
PHC Medical Care Team Member